Similar articles

• [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].

  Mazeron MC. Mazeron MC. Bull Cancer Radiother. 1996;83(1):3-7. Bull Cancer Radiother. 1996. PMID: 8679277 Review. French.
• Nasopharyngeal carcinoma: significance of changes in Epstein-Barr virus-related antibody patterns following therapy.

  Henle W, Ho JH, Henle G, Chau JC, Kwan HC. Henle W, et al. Int J Cancer. 1977 Nov 15;20(5):663-72. doi: 10.1002/ijc.2910200504. Int J Cancer. 1977. PMID: 200569 No abstract available.
• Presence of Epstein-Barr virus specific IgA in saliva of nasopharyngeal carcinoma patients: their activity, origin and possible clinical value.

  Desgranges C, de-The G. Desgranges C, et al. IARC Sci Publ (1971). 1978;(20):459-69. IARC Sci Publ (1971). 1978. PMID: 215528 No abstract available.
• Clinical evaluation of EBV serology in American patients with nasopharyngeal carcinoma.

  Pearson GR, Coates HL, Neel HB 3rd, Levine P, Ablashi D, Easton J. Pearson GR, et al. IARC Sci Publ (1971). 1978;(20):439-48. IARC Sci Publ (1971). 1978. PMID: 215526
• Epstein-Barr virus serologic testing: diagnostic indications and interpretations.

  Sumaya CV. Sumaya CV. Pediatr Infect Dis. 1986 May-Jun;5(3):337-42. doi: 10.1097/00006454-198605000-00013. Pediatr Infect Dis. 1986. PMID: 3014456 Review. No abstract available.